Cargando…

Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy

Background. It is often difficult to differentiate Parkinson's disease (PD) from multiple system atrophy (MSA), especially in their early stages. Objectives. To examine the clinical utility of histopathological analysis of biopsied skin from the chest wall and/or leg in differentiating between...

Descripción completa

Detalles Bibliográficos
Autores principales: Haga, Rie, Sugimoto, Kazuhiro, Nishijima, Haruo, Miki, Yasuo, Suzuki, Chieko, Wakabayashi, Koichi, Baba, Masayuki, Yagihashi, Soroku, Tomiyama, Masahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402568/
https://www.ncbi.nlm.nih.gov/pubmed/25945280
http://dx.doi.org/10.1155/2015/167038
_version_ 1782367278946320384
author Haga, Rie
Sugimoto, Kazuhiro
Nishijima, Haruo
Miki, Yasuo
Suzuki, Chieko
Wakabayashi, Koichi
Baba, Masayuki
Yagihashi, Soroku
Tomiyama, Masahiko
author_facet Haga, Rie
Sugimoto, Kazuhiro
Nishijima, Haruo
Miki, Yasuo
Suzuki, Chieko
Wakabayashi, Koichi
Baba, Masayuki
Yagihashi, Soroku
Tomiyama, Masahiko
author_sort Haga, Rie
collection PubMed
description Background. It is often difficult to differentiate Parkinson's disease (PD) from multiple system atrophy (MSA), especially in their early stages. Objectives. To examine the clinical utility of histopathological analysis of biopsied skin from the chest wall and/or leg in differentiating between the two diseases. Methods. Skin biopsies from the lower leg and/or anterior chest wall were obtained from 38 patients with idiopathic PD (26 treated with levodopa and 12 levodopa-naïve) and 13 age-matched patients with MSA. We sought aggregates of phosphorylated α-synuclein on cutaneous nerve fibers using double fluorescence immunohistochemistry and confocal microscopy and measured intraepidermal nerve fiber density (IENFD). Results. Phosphorylated α-synuclein aggregates were identified on cutaneous nerves in two patients with PD (5.3%) but in none of the patients with MSA, and IENFD was significantly lower in patients with PD when compared to those with MSA. There was no difference in IENFD between levodopa-treated and levodopa-naïve patients with PD. Conclusions. Our findings suggest that an assessment of IENFD in biopsied skin could be a useful means of differentiating between PD and MSA but that detection of α-synuclein aggregates on cutaneous nerves in the distal sites of the body is insufficiently sensitive.
format Online
Article
Text
id pubmed-4402568
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-44025682015-05-05 Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy Haga, Rie Sugimoto, Kazuhiro Nishijima, Haruo Miki, Yasuo Suzuki, Chieko Wakabayashi, Koichi Baba, Masayuki Yagihashi, Soroku Tomiyama, Masahiko Parkinsons Dis Research Article Background. It is often difficult to differentiate Parkinson's disease (PD) from multiple system atrophy (MSA), especially in their early stages. Objectives. To examine the clinical utility of histopathological analysis of biopsied skin from the chest wall and/or leg in differentiating between the two diseases. Methods. Skin biopsies from the lower leg and/or anterior chest wall were obtained from 38 patients with idiopathic PD (26 treated with levodopa and 12 levodopa-naïve) and 13 age-matched patients with MSA. We sought aggregates of phosphorylated α-synuclein on cutaneous nerve fibers using double fluorescence immunohistochemistry and confocal microscopy and measured intraepidermal nerve fiber density (IENFD). Results. Phosphorylated α-synuclein aggregates were identified on cutaneous nerves in two patients with PD (5.3%) but in none of the patients with MSA, and IENFD was significantly lower in patients with PD when compared to those with MSA. There was no difference in IENFD between levodopa-treated and levodopa-naïve patients with PD. Conclusions. Our findings suggest that an assessment of IENFD in biopsied skin could be a useful means of differentiating between PD and MSA but that detection of α-synuclein aggregates on cutaneous nerves in the distal sites of the body is insufficiently sensitive. Hindawi Publishing Corporation 2015 2015-04-06 /pmc/articles/PMC4402568/ /pubmed/25945280 http://dx.doi.org/10.1155/2015/167038 Text en Copyright © 2015 Rie Haga et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Haga, Rie
Sugimoto, Kazuhiro
Nishijima, Haruo
Miki, Yasuo
Suzuki, Chieko
Wakabayashi, Koichi
Baba, Masayuki
Yagihashi, Soroku
Tomiyama, Masahiko
Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy
title Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy
title_full Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy
title_fullStr Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy
title_full_unstemmed Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy
title_short Clinical Utility of Skin Biopsy in Differentiating between Parkinson's Disease and Multiple System Atrophy
title_sort clinical utility of skin biopsy in differentiating between parkinson's disease and multiple system atrophy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402568/
https://www.ncbi.nlm.nih.gov/pubmed/25945280
http://dx.doi.org/10.1155/2015/167038
work_keys_str_mv AT hagarie clinicalutilityofskinbiopsyindifferentiatingbetweenparkinsonsdiseaseandmultiplesystematrophy
AT sugimotokazuhiro clinicalutilityofskinbiopsyindifferentiatingbetweenparkinsonsdiseaseandmultiplesystematrophy
AT nishijimaharuo clinicalutilityofskinbiopsyindifferentiatingbetweenparkinsonsdiseaseandmultiplesystematrophy
AT mikiyasuo clinicalutilityofskinbiopsyindifferentiatingbetweenparkinsonsdiseaseandmultiplesystematrophy
AT suzukichieko clinicalutilityofskinbiopsyindifferentiatingbetweenparkinsonsdiseaseandmultiplesystematrophy
AT wakabayashikoichi clinicalutilityofskinbiopsyindifferentiatingbetweenparkinsonsdiseaseandmultiplesystematrophy
AT babamasayuki clinicalutilityofskinbiopsyindifferentiatingbetweenparkinsonsdiseaseandmultiplesystematrophy
AT yagihashisoroku clinicalutilityofskinbiopsyindifferentiatingbetweenparkinsonsdiseaseandmultiplesystematrophy
AT tomiyamamasahiko clinicalutilityofskinbiopsyindifferentiatingbetweenparkinsonsdiseaseandmultiplesystematrophy